{"organizations": [], "uuid": "9c898e0b714fc737df4d113c1656d2416996014a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180122.html", "section_title": "Archive News &amp; Video for Monday, 22 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-genmab-gets-usd-50-mln-from-novart/brief-genmab-gets-usd-50-mln-from-novartis-for-lost-potential-milestones-and-royalties-idUSASM000IBS", "country": "US", "domain_rank": 408, "title": "BRIEF-Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.297, "site_type": "news", "published": "2018-01-22T15:15:00.000+02:00", "replies_count": 0, "uuid": "9c898e0b714fc737df4d113c1656d2416996014a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-genmab-gets-usd-50-mln-from-novart/brief-genmab-gets-usd-50-mln-from-novartis-for-lost-potential-milestones-and-royalties-idUSASM000IBS", "ord_in_thread": 0, "title": "BRIEF-Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​", "locations": [], "entities": {"persons": [{"name": "genmab", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 22 (Reuters) - GENMAB:\n* ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS\n* ‍RECEIVES USD 50 MILLION FROM NOVARTIS AS PAYMENT FOR LOST POTENTIAL MILESTONES AND ROYALTIES​\n* ‍AMOUNT WILL BE INCLUDED IN GENMAB‘S 2018 GUIDANCE​\n* ‍ROYALTIES WILL CONTINUE TO BE EARNED ON NET SALES OF ARZERRA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-22T15:15:00.000+02:00", "crawled": "2018-01-23T17:56:19.003+02:00", "highlightTitle": ""}